Here are four observations:
1. Biologics’ popularity among spine surgeons will drive the market, along with the minimally invasive nature of the procedure and a growing geriatric population.
2. Currently, North America holds the largest market share, with Europe coming in second, due to advanced technologies and high per capita income.
3. The Asian-Pacific market is set to grow at a high rate because of an increasing population, better medical coverage and growing demand in India and China.
4. Key market players include Alphatec Spine, DePuy Synthes, Medtronic, Stryker, Smith & Nephew, Orthovita, Zimmer Biomet, K2M, NuVasive, Lattice Biologics, Arthrex, DMP Spine, Orthofix, RTI Surgical, Wright Medical Technology, Cesca Therapeutics and Precision Spine.
More articles on devices:
Conventus Orthopaedics names new CEO — 4 things to know
Mazor Robotics, Stryker, K2M & more: 19 device company key notes
Vertebral compression fracture devices market to reach $1.1M by 2022: 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
